IPC Education Hub
Interactive clinical education on neuromodulation and interventional psychiatry, built from the IPC lecture series.
A living resource that keeps evolving
Every new lecture is screened against every existing module before anything is added. Content is merged, sharpened, or replaced wherever newer material is stronger, and insights are carried into every section they touch, not only the one they came from. As new lectures and updates arrive, the summaries, clinical pearls, questions, and cases keep changing with the field.
Summaries & clinical pearls
Structured overviews of each modality, with pearls on patient selection, parameters, safety, and evidence.
Review questions
Multiple-choice questions at foundational, intermediate, and advanced levels, with an explanation for every answer choice.
Case simulations
Step-by-step clinical decision points covering patient selection, treatment choices, and complications.
Transcranial Magnetic Stimulation
Delivery of magnetic pulses over the scalp to stimulate the brain directly — modulating cortical excitability and depression-relevant circuits without surgery, anesthesia, or systemic side effects.
Device, Mechanism & Setup
- Figure-8 coil generates magnetic pulse → electrical field at cortex; coil shape, placement, and frequency vary by indication
- Motor thresholding over motor cortex establishes cortical excitability — used to dose every patient individually; not one-size-fits-all
- Left DLPFC is hypoactive in depression; subgenual anterior cingulate (sgACC) is hyperactive — these are the core circuit targets for TMS in MDD
- TMS development followed an experimental-medicine path: frontal hypometabolism with left-greater-than-right asymmetry was framed as a response biomarker, and frequency-specific protocols (high frequency to raise the left, low frequency to lower the right) were built to undo it; prefrontal sites are now understood as entry points into a distributed network, and alpha-rhythm asymmetry is a further proposed response biomarker
- TMS is a technology rather than a single treatment — different protocols are different treatments — and early data suggest individual alpha peak frequency may guide protocol choice: a peak near 10 Hz favors response to a 10 Hz protocol, while a peak closer to 8 or 12 Hz predicts weaker response and may favor another protocol
Protocols: Standard vs Theta Burst
- Standard 10 Hz protocol: 37 minutes per session; theta burst (iTBS): 3 minutes 9 seconds — non-inferior efficacy with dramatically improved throughput (3× patients per hour); most TMS manufacturers now support iTBS
- iTBS: 50 Hz triplets at 5 Hz intervals — mimics cortical theta rhythms; cTBS is suppressive (≈1 Hz); excitatory/inhibitory binary is likely an oversimplification at the DLPFC
- Key stimulation parameters: pulse frequency, pulse shape (monophasic vs biphasic), charge per pulse, inter-train interval, and motor threshold % — all interact; SAINT uses 90% rMT with depth correction, conventional iTBS typically uses 120% rMT
- D-cycloserine (NMDA partial agonist) augmentation of iTBS: 74% vs 29% response in RCT — NMDA receptor dependence of TBS plasticity is the mechanistic rationale; requires replication
- "More is more" signal: non-responders to a 4-week course who continued twice-weekly TMS showed ongoing response accumulation through week 8 — no clear ceiling observed, supporting the scientific rationale for accelerated approaches
Indications, Evidence, Safety & Targeting
- FDA-cleared: MDD, anxiety comorbid with MDD, refractory OCD, smoking cessation, migraine with aura — coil type and placement differ across indications
- Standard course: 36 sessions, most insurances cover; seizure risk and hearing loss without ear protection are primary safety risks; headache and scalp discomfort most common side effects
- Targeting methods: 5 cm rule → BeamF3 → adjusted BeamF3 → fMRI-based (used in SAINT); tape measure methods are cheap/accessible but anatomically imprecise
- Real-world effectiveness: in an open-label study of 339 complex patients (comorbid anxiety, hypertension, diabetes, concurrent medications) treated with the original 37-minute 10 Hz protocol, response was roughly 40–58% and remission 26–37% depending on the outcome measure; the figures remain valid for 10 Hz, 1 Hz, and once-daily iTBS
- Head-to-head evidence: two trials in patients who had failed at least two medications (one US-based, one in the Netherlands) found TMS more effective than switching or augmenting medication or the guideline-based next step; the FDA label requires failure of one or more medications, yet most payers still require four or more — with some beginning to lower the threshold to two
Clinical Pearls — TMS Overview
Review Questions — TMS Overview
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — TMS Overview
Stepwise clinical vignettes. Explore all options freely before continuing.
Accelerated TMS & SAINT
Protocols delivering multiple TMS sessions per day over a compressed timeframe — dramatically shortening treatment duration while potentially exceeding the efficacy of conventional 6-week courses.
SAINT Protocol & fMRI Targeting
- 10 sessions/day × 5 days; 1,800 pulses/session (3× conventional iTBS); ~50-min inter-session interval; delivers 90,000 total pulses vs 18,000 in conventional 30-session course
- Resting-state fMRI identifies the DLPFC subregion with maximum negative connectivity to sgACC — anti-correlated targeting; overcomes the anatomical imprecision of tape-measure methods
- 90% resting motor threshold with depth correction (adjusting for scalp-to-cortex distance at DLPFC vs motor cortex) — often results in higher effective stimulation than the 90% figure suggests
Clinical Evidence
- Open-label: 90.5% remission at 4 weeks (86.4% ITT); double-blind RCT (n=29): 78.6% remission active vs 13.3% sham — striking separation from placebo unlike many antidepressant trials
- Durability at 12 weeks: 47% remained in remission, 43% remained responders — comparable to acute remission rates of conventional protocols in similar populations
- Retreatment: 74% remitted after both first and second SAINT courses; index and retreatment courses showed similar efficacy — supports repeat use when patients relapse
Maintenance, Safety & Unanswered Questions
- Continuation paradigm: algorithm-guided additional SAINT days (avg 15 over 12 months); 85% of monitoring period in remission — potential path to sustained wellness without indefinite daily treatment
- Safety: no seizures reported in research or clinical SAINT use; most common side effects fatigue, headache, scalp pain — similar profile to conventional TMS; no negative cognitive effects on neuropsych testing
- The targeting question has now been answered in part: a head-to-head trial holding the accelerated schedule constant while randomizing connectivity-based vs scalp-based targeting found 83% vs 62% median MADRS improvement (roughly 80% vs 60% response), establishing that targeting contributes independently of pulse volume and session count
- Sessions vs pulses: twice-daily iTBS (600 pulses × 2) vs once-daily 1200 pulses showed no clinical difference — same-day pulse doubling may not add benefit beyond a single higher-dose session; suggests it may be total pulses rather than session count that matters, though parameters are fundamentally interrelated
- Accelerated without neuronavigation: open-label pilot (n=21) using 36 sessions over 5 days with BeamF3 targeting (standard 600 pulses/session, 60-min intervals) achieved 70% response and 55% remission at 4 weeks — simpler to implement than full SAINT but potentially stronger than conventional 6-week course
Clinical Pearls — Accelerated TMS & SAINT
Review Questions — Accelerated TMS & SAINT
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Accelerated TMS & SAINT
Stepwise clinical vignettes. Explore all options freely before continuing.
Circuit Targeting & Neuroimaging
Using lesion network mapping and functional connectivity to identify where to stimulate — moving target selection from scalp measurement to circuit identification, across symptoms, disorders, and stimulation modalities.
Lesion Network Mapping & Causal Inference
- Lesions causing the same symptom frequently do not overlap anatomically, but mapping each lesion onto a normative connectome shows they often connect to one shared network
- Core hypothesis: if disrupting a circuit causes a symptom, stimulating that circuit may relieve it — the framework behind most current circuit-derived stimulation targets; because a stimulation site is an entry point into the network, well-connected hub nodes offer the best chance of circuit-wide effect
- Convergence across lesions, TMS, and DBS is what licenses causal inference — each source has different confounders, so agreement across all three excludes explanations unique to any one
- Normative connectome estimation is a real limitation but an acceptable approximation, because between-subject variance in lesion location far exceeds variance in network architecture
- The method has now re-derived established targets for parkinsonism, tics, seizures, vertigo, tremor, and addiction, and is generating novel candidates where no target previously existed
The Depression Circuit & Personalized Targeting
- Antidepressant efficacy of a stimulation site tracks its anti-correlation with the subgenual anterior cingulate — established in 2012, replicated prospectively, and the basis for fMRI-guided protocols
- The convergent depression circuit already underlies the 5 cm rule, 6 cm rule, and BeamF3, plausibly explaining why decades of scalp-target refinement produced only modest gains
- Individualized connectivity peaks outperform scalp landmarks across at least six retrospective cohorts (meta-analytic weighted r ≈ −0.28, n = 391); weaker effects track lower-resolution imaging, and no study has found the reverse
- Randomized head-to-head trial: 83% vs 62% median MADRS improvement (≈80% vs 60% response) for connectivity-based vs scalp-based targeting, with a number needed to scan of about 5
- A real-world clinic cohort reproduced the same ~20-point response gap after implementing fMRI guidance, with guidance the only variable predicting outcome after adjustment
The Anxiety Circuit & Symptom-Specific Target Selection
- Data-driven clustering of symptom-level outcomes separated two circuits — initially dysphoric and anxiosomatic, later validated against dedicated anxiety scales as depression and anxiety circuits
- The two circuits are close to anti-correlated, predicting that harder engagement of the depression circuit can worsen anxiety — consistent with a 20% treatment-emergent anxiety rate in the largest TMS trial
- In patients with both depression and anxiety, a randomized active-controlled trial found the anxiety target superior for anxiety (58% vs 36% median BAI improvement) and equivalent for depression
- Two incidental trials independently support the pattern, including a negative DMPFC trial whose comorbid-anxiety subgroup separated from sham while the non-anxious subgroup did not
- Cross-modality implications: H1 and H7 deep TMS coils preferentially engage different circuits, and subthalamic DBS contacts differ in anxiety effect while remaining equivalent for motor symptoms
Clinical Pearls — Circuit Targeting & Neuroimaging
Review Questions — Circuit Targeting & Neuroimaging
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Circuit Targeting & Neuroimaging
Stepwise clinical vignettes. Explore all options freely before continuing.
Psychedelics & Psychedelic-Assisted Psychotherapy
Serotonin 2A receptor agonists and related compounds that, combined with structured psychotherapeutic support, may produce rapid and durable therapeutic effects in depression, PTSD, and other treatment-resistant conditions — with a complex evidence base, significant methodological challenges, and a rapidly evolving regulatory landscape.
Mechanisms & Compounds
- Classic psychedelics: 5-HT2A agonism → downstream glutamate release, mTOR/BDNF activation, neurogenesis/synaptogenesis — mechanism parallels with ketamine but via different receptor entry point
- Additional proposed mechanisms: anti-inflammatory effects, reopening of developmental critical periods, increased cognitive flexibility and emotional processing flexibility, default mode network disruption
- Non-classic psychedelics: MDMA (amphetamine derivative, primarily monoaminergic), ibogaine (potent plant alkaloid, requires intensive cardiac monitoring — acute effects last ~30 hours), salvia — similar subjective experiences, different receptor profiles
- Psychedelics as "non-specific amplifiers" (Tim Leary): they amplify both the contents of consciousness and the methodological problems inherent to psychiatric research
Clinical Evidence & Methodological Challenges
- Hopkins psilocybin for MDD (n=24, waiting-list control): large effect sizes at 1–4 weeks post-treatment, maintained through 12 months; ~5-year follow-up survey shows sustained low depression scores — remarkable durability in a small study
- Largest TRD psilocybin trial to date: 25 mg > 10 mg > 1 mg (placebo-equivalent) at 3 weeks for COMP360; statistical significance lost at 6 weeks in pre-specified model; 3 suicidal behaviors in high-dose group, all in non-responders with prior self-harm history
- MDMA for PTSD (MAPS/Lykos): FDA rejected 2024 — failures to collect drug-liking data, ~40% prior MDMA exposure creating expectancy bias, concerns about therapist conduct in sessions, and durability of benefit beyond 18 weeks
- Functional unblinding is near-universal: 90%+ of participants and staff can identify treatment arm; nosebo effects in those who believe they received placebo can inflate active-arm effect sizes
- Therapy confounding: psychedelic trials involve many hours of preparation, dosing-day support, and integration — therapeutic alliance, expectancy, and non-pharmacologic factors almost certainly contribute; how much is unknown; no RCT design can fully disentangle them
- Sample representativeness: 2018 review found 82% of psychedelic trial participants were non-Hispanic white, higher SES — evidence base may not generalize; racial disparity in naturalistic benefit data noted in survey studies
Implementation, Ethics & Regulatory Landscape
- Cost: MAPS/Lykos MDMA therapy estimated at $11,000–12,000/patient, mostly therapist time (drug is inexpensive); break-even for insurers approximately 4 years — difficult coverage argument; initial access likely limited to those who can self-pay
- Delivery model: two-therapist model is resource-intensive and limits access but has the strongest safety track record; alternatives under investigation include single therapist, group therapy, and AI/technology-assisted monitoring
- Training gap: less than 50% of residency programs provide didactics on psychedelics; no consensus on required competencies; tri-institutional initiative (Hopkins, Yale, NYU) developing modular curriculum and fellowship framework
- Ethical concerns: heightened suggestibility during sessions increases risk of boundary violations and internalization of therapist expectations; MAPS trials documented a case of serious misconduct involving an unlicensed therapist; use of supportive touch is common and creates a "slippery slope" requiring careful institutional policy
- Legal/regulatory landscape: rapidly evolving; Oregon (psilocybin, 2023) and Colorado have legalized "supported adult use"; ~15,000 served in Oregon since launch; New York legislation pending; international: Australia approved limited therapeutic use; many countries allow ritual use
- Access pathways outside clinical trials: state/local legalization, religious use exemptions (federally sanctioned for a small number of entities), international retreat centers, and underground providers (estimated thousands in the US)
- Psychiatrist's role: lead teams rather than sit for 8-hour sessions; expertise in psychopharmacology (drug interactions, patient selection, serious adverse events); recognize and distinguish afterglow from hypomania/mania; coordinate master's-level therapists, nurses, and mid-level providers who will likely staff dosing sessions
Clinical Pearls — Psychedelics Overview
Review Questions — Psychedelics Overview
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Psychedelics Overview
Stepwise clinical vignettes. Explore all options freely before continuing.
Pediatric, Adolescent & Neurodivergent Populations
Interventional psychiatry in children, adolescents, and neurodivergent individuals requires a distinct clinical framework — not a scaled-down adult approach. The four pillars of practice: rigorous developmentally-informed Assessment, equitable Access, thoughtful Augmentation of existing care, and unwavering Advocacy for the patient.
Treatment Resistance & Assessment in Youth
- TRD in adolescents: failure of one adequate antidepressant trial + evidence-based psychotherapy may warrant IPS referral; two failed trials = treatment-refractory — thresholds are lower than adult standards given only two FDA-approved medications
- ASD "treatment resistance" reflects neurobiological differences (elevated blood serotonin, reduced CNS serotonin receptors) — not simply medication non-compliance; polypharmacy burden is high and IPS may reduce it
- Rating instruments must be adapted: DAS-21 shows better validity for neurodivergent individuals; Pediatric Catatonia Rating Scale preferred over Bush-Francis in youth; catatonia in autism presents as regression and self-injury, not just staring and rigidity
- Evaluations must be holistic — psychological testing, play-based assessment, school/family collateral, and observational data are all clinically valid inputs, not administrative add-ons
Modality-Specific Considerations: ECT, TMS & Ketamine
- ECT: indications mirror adults (catatonia, TRD, psychotic depression, NMS) — intellectual disability and SIB alone are NOT indications; children have lower seizure thresholds, higher rates of prolonged and TARDIVE seizures; state probate laws vary (CA: 12, TN: 14, TX: 16)
- TMS: FDA cleared (2024) for MDD in adolescents ages 15–21; developmentally informed adaptations are essential (first-then boards, preferred videos, desensitization, behavioral rewards); no single optimal target in ASD — multiple networks are implicated
- Ketamine/esketamine: neither is FDA approved for depression in youth; Spravato explicitly excludes ASD; emerging case reports and early trial data show rapid antidepressant effects — use remains off-label with heightened safeguards required
- Catatonia prevalence in autism is up to 17% — screen proactively; ECT for catatonia in neurodivergent patients is evidence-based when benzodiazepines fail
The Four A’s: Assess, Access, Augment, Advocate
- Assess: developmentally grounded, multi-source evaluations — standard adult instruments may be insufficient; play-based and observational data are valid; family and school are irreplaceable collateral sources
- Access: workforce shortages, insurance gaps, and geographic barriers are real — not enough child psychiatrists nationally; authorization pathways for pediatric TMS and esketamine remain underdeveloped
- Augment: IPS in children rarely replaces existing care — it augments and can reduce polypharmacy; comorbidity is the rule; multimodal coordination across school, family, therapist, and pediatrician is essential
- Advocate: the interventionist’s role extends beyond the treatment room — probate navigation, insurance appeals, mental health parity enforcement, and systemic equity are all within scope
Clinical Pearls — Special Populations Overview
Review Questions — Special Populations Overview
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Special Populations Overview
Stepwise clinical vignettes. Explore all options freely before continuing.
Vagus Nerve Stimulation
An implanted neurostimulator delivering intermittent electrical pulses to the left cervical vagus nerve, relaying signals through the nucleus tractus solitarius to monoamine-producing brainstem centers and limbic cortex — a bottom-up approach to treatment-resistant depression and epilepsy.
Mechanism & Anatomy
- ~80% of vagus nerve fibers are afferent (periphery → brain); afferent fibers have lower stimulation thresholds — left-sided stimulation primarily avoids visceral efferent effects, minimizing side effects
- Primary relay: nucleus tractus solitarius (NTS) → locus coeruleus (NE), dorsal raphe (5-HT), parabrachial nucleus (CRF) → hippocampus, amygdala, thalamus, anterior insula, ventrolateral PFC, infralimbic cortex
- Circuit effects overlap with DBS targets: VNS modulates the same limbic-prefrontal networks implicated in depression — connecting bottom-up brainstem drive to top-down cortical dysregulation
Parameters, Titration & Safety
- Four independently adjustable parameters: output current (mA), pulse width (µsec), frequency (Hz), duty cycle (ON/OFF time ratio); typical maintenance: 20 Hz, 250 µsec, 30 sec ON / 5 min OFF (10% duty cycle)
- Titration is imprecise — individual differences in nerve anatomy, electrode positioning, and tissue conductivity mean identical parameters produce different effective stimulation across patients; clinicians titrate against side effects
- Most common adverse effect: hoarseness/voice change (27–68%), caused by stimulation of the left recurrent laryngeal nerve; occurs in real time during ON cycles and typically improves over 12–24 months; absolute contraindications: prior bilateral or left vagotomy, diathermy near the device
Evidence & Access Challenges
- Landmark RCTs: Rush et al. 2005 (27% response/16% remission at 12 mo); Conway et al. 2025 — RECOVER trial (19% vs 16% active vs sham at 12 mo — no primary endpoint separation); Aaronson et al. 2013 (35–48% response / 20–23% remission in parallel design)
- Critical limitation: VNS takes months to years to exert antidepressant effects — 10-week sham-controlled periods miss the window where separation would emerge; raising ethical concerns about extending sham periods in severely ill populations
- Battery life 4–8 years depending on settings; rechargeable models now available; MRI compatibility is device- and field-strength-dependent — always consult manufacturer before imaging; VNS does not preclude TMS in most cases (ferromagnetism of device determines safety, not the mere presence of the device)
Clinical Pearls — VNS Overview
Review Questions — VNS Overview
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — VNS Overview
Stepwise clinical vignettes. Explore all options freely before continuing.
Deep Brain Stimulation
Continuous high-frequency electrical stimulation delivered via surgically implanted leads targeting discrete subcortical and white matter nodes — modulating dysfunctional neural networks in treatment-resistant depression and OCD through volumetric activation of connected circuits rather than focal ablation.
Circuit Targets & Network Rationale
- Four depression-relevant dysfunctional networks: affective (hyperconnected: sgACC–amygdala–insula–OFC → depressed mood); default mode (hyperconnected: mPFC–PCC–IPC–precuneus → rumination); reward (hypoconnected: NAcc–PFC → anhedonia); cognitive control (hypoconnected: dACC–dlPFC → executive dysfunction)
- Major MDD DBS targets: SCC/BA25 (most studied), VC/VS (NAcc/ALIC), ITP/BNST, LHb, slMFB — each sits at a white matter confluence connecting multiple depression-relevant networks; stimulation VTA of ~3 mm can propagate through normative connectome to modulate distal cortical regions
- Target selection is currently not biomarker-driven — adapted from movement disorder protocols or designed to evoke intraoperative emotional response; this imprecision is a major limitation and active research frontier
Parameters, Titration & Stimulation Modes
- High frequency (100–130 Hz) is standard — justified by temporal summation: repeated sub-threshold EPSPs progressively depolarize the postsynaptic membrane until threshold is crossed; low-frequency stimulation has not produced benefit in psychiatric targets (its use is limited to select Parkinson disease gait and cognitive symptoms)
- Two stimulation modes: monopolar (IPG = anode, lead contact = cathode → spherical field, larger VTA, lower threshold but more adjacent structure activation) vs bipolar (contacts serve as anode/cathode → ellipsoid field, smaller VTA, more focal, higher threshold)
- Titration: check impedance first (high impedance = broken lead, fibrosis, or infection — infection can be delayed months post-implant); then systematically test each contact across amplitude range, mapping therapeutic window (benefit threshold vs adverse effect threshold) per contact; optimal contact is the one with the widest therapeutic window
Evidence, Adverse Effects & Future Directions
- Key RCTs (depression): Holtzheimer 2017/SCC (42%/25% R/Rem at 30 mo); Ramasubbu 2020/SCC (50%/27% at 12 mo); Coenen 2019/slMFB (100%/50% — small pilot); Dougherty 2015/VC-VS (23%/20%); all small samples, most blinded phases non-significant
- Psychiatric adverse effects (depression population): suicide attempt 3–16% (most likely reflects underlying illness severity, not device causation); depression 2–43%; hypomania/mania 1–23%; gait disturbance 5–36%; seizure 2–3%; cognitive effects common but often transient
- Future directions: personalized preoperative biomarkers (facial expression, speech, wearables, fMRI); tractography-guided targeting; closed-loop DBS using local field potential beta-band recordings as sensing biomarkers to trigger stimulation only during symptomatic periods — representing a potential paradigm shift from continuous open-loop to adaptive, demand-driven stimulation
Clinical Pearls — DBS Overview
Review Questions — DBS Overview
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — DBS Overview
Stepwise clinical vignettes. Explore all options freely before continuing.
Circuit-Specific DBS & Tractography
How psychiatric DBS evolved from landmark-based lead placement to patient-specific engagement of white matter pathways — across depression, OCD, and symptom-specific network targets — and what that changes for programming, troubleshooting, and patient selection.
From Landmarks to Pathways: Depression Targeting
- SCC DBS was designed to down-regulate a metabolically defined node, not to replace a lesion — area 25 decreased across successful treatments, and its effects are distributed across the brain
- Landmark targeting helped about 60% of ECT-failure patients, but contact location in standard space did not separate responders from non-responders; non-responders lacked remote network changes
- Modeled-stimulation tractography yields a common responder map of four bundles — cingulum, frontostriatal fibers, forceps minor, uncinate fasciculus — and individual contacts 1.5 mm apart can engage different tracts
- Prospective tractography guidance raised response from about 41% to 73–90%; a pooled analysis (n=143) implicated missed left cingulum engagement, and the successor trial randomizes only after the target is confirmed
- The same functional-connectivity logic links DBS and TMS sites, and the DLPFC TMS target should avoid the default-mode portion of DLPFC
OCD and Symptom-Specific Network Targeting
- Accumbens-era OCD DBS gave about 52% response (n=70) over 10 to 600 days, with insomnia (46%) and hypomania (25%) and often two active contacts
- Responders were stimulated in ALIC white matter, and the tract engaged (anterior thalamic radiation vs medial forebrain bundle) varies by patient despite identical structural lead positions
- Tractography-guided ALIC DBS reached 85% response (24/28) with a single fixed contact; the common map includes prefrontal cortex, thalamus, STN, brainstem, and GPe
- The target is specific for compulsivity, so non-responders likely need a different network, and a lower limbic contact can address comorbid depression or anhedonia
- Symptom constructs map to networks — negative affect to SCC, compulsivity to ALIC, reward to medial forebrain bundle/ventral striatum — with preliminary extensions to schizophrenia and Parkinson apathy
Programming, Troubleshooting & Patient Selection
- On target, stimulation is set near 130 Hz and 90 µs on one contact; current and time are the dose levers, up to a ceiling around 6 mA, guided by a local field potential readout
- Frequency and pulse-width changes have not produced benefit in psychiatric targets; low-frequency stimulation is used mainly for gait and cognitive symptoms in Parkinson disease
- Reproducible stimulation-evoked potentials verify target engagement and help estimate a starting dose; adjacent contacts may give different signals
- Leads can be pulled up but not pushed deeper; off-trajectory or shallow leads require re-implantation, with position confirmed by intraoperative imaging
- Retrospective baseline connectivity (SCC–mid-cingulate, ventral striatum–insula) may flag likely non-responders, and SCC connectivity predicts CBT versus medication response — emerging, not yet validated
Clinical Pearls — Circuit-Specific DBS & Tractography
Review Questions — Circuit-Specific DBS & Tractography
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Circuit-Specific DBS & Tractography
Stepwise clinical vignettes. Explore all options freely before continuing.
Electroconvulsive Therapy & Magnetic Seizure Therapy
Seizure-based treatments that remain among the most effective interventions in psychiatry — ECT induces generalized seizures using scalp electrodes; MST uses a magnetic coil to achieve focal seizures with markedly reduced cognitive side effects.
Dosing: Spatial & Temporal Parameters
- Electrode placement controls the spatial distribution of the electric field in the brain — bilateral temporal (BT) spreads broadly; right unilateral (RUL) and bifrontal (BF) are more sparing of the left temporal lobe; all conventional placements stimulate the hippocampus above neural depolarization threshold
- Pulse width is a key driver of cognitive side effects: ultra-brief (0.25–0.3 ms) reduces amnesia dramatically vs. brief pulse (1–2 ms) by inducing seizures at lower total charge and differentially activating axons vs. soma based on their different time constants
- All electrical parameters matter independently — stimulation strength, electrode configuration, pulse characteristics, and train characteristics all have unique physiological contributions; you cannot substitute one for another
- Current optimal balance: 6× seizure threshold RUL ECT + ultra-brief pulse — matches BL ECT efficacy (~71% responders, ~62% remitters) with significantly less amnesia (p<0.0001)
- Anatomical variability means the same current delivers very different electric fields across patients — individualized amplitude titration (iLAST) and simulated E-field modeling may improve dosing precision
Mechanism: E-field vs. Seizure
- Three competing models: (A) seizure drives efficacy, E-field drives side effects; (B) E-field drives efficacy, seizure drives side effects; (C) E-field × seizure interaction drives outcomes
- MST tests Model A — by using magnetic stimulation to induce seizures with minimal intracranial E-field, it lowered cognitive side effects without sacrificing antidepressant efficacy, providing the strongest human evidence to date in support of Model A
- TEST (Transcranial Electric Stimulation Therapy) tests Model B — delivers ECT-strength E-fields using bifrontal placement without inducing seizure; first double-blind RCT is underway
- MIST (Multichannel Individualized Stimulation Therapy) enables Model C testing — 15 independent current sources allow multi-focal stimulation patterns tailored to target efficacy circuits while sparing memory circuits; integrated with EEG for seizure monitoring
- ECT increases brain volume in a regionally specific manner and volume increases correlate with E-field strength — whether E-field alone causes this (or requires seizure) is the open question the TEST trial is designed to answer
MST Evidence & Future Directions
- MST vs RUL ultra-brief ECT (JAMA Psychiatry 2023, n=73): 45% vs 42% remission — non-inferior efficacy with faster reorientation (p<0.01 at threshold, p<0.0001 at suprathreshold) and significantly less anterograde and retrograde amnesia (significant for ECT, not for MST)
- CREST-MST trial (R01MH112815, NCT03191058) is a larger non-inferiority RCT vs ECT — results pending; FDA has provided guidance on what evidence would support MST device approval
- Novel mechanism: cortical spreading depression (CSD) — a slowly propagating depolarization wave — occurs after ECT-induced seizures in both mouse models and human optical neuroimaging; its contribution to ECT efficacy or side effects is unexplored and may add a third mechanism beyond E-field and seizure
- Understudied parameters include stimulus frequency (U-shaped seizure threshold curve suggests mid-range frequencies are most efficient), waveform shape (biphasic, multiphasic, pre-polarized), and current directionality (unidirectional trains more efficient than bidirectional in NHP studies)
Clinical Pearls — ECT / MST Overview
Review Questions — ECT / MST Overview
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — ECT / MST Overview
Stepwise clinical vignettes. Explore all options freely before continuing.
Ketamine & Esketamine
Glutamatergic agents that produce rapid, robust antidepressant effects — ketamine (racemic IV) and esketamine (intranasal Spravato) represent a mechanistic departure from monoaminergic antidepressants and the first new pharmacological approach to TRD in decades.
Mechanism & Pharmacology
- Primary mechanism: NMDA receptor antagonism on GABAergic interneurons → disinhibition of glutamate transmission → AMPA receptor activation → BDNF/TrkB signaling → synaptic plasticity and antidepressant effect; ketamine reverses stress-induced dendritic atrophy in medial prefrontal cortical neurons in animal models
- Mu-opioid receptor involvement is an active area of investigation — naltrexone appears to attenuate ketamine's effects in some studies, but the mechanism may involve a functioning endogenous opioid system (beta-endorphin/BDNF pathway) rather than direct ketamine-opioid binding
- Subjective experience (awe, mystical-type states) may independently contribute to antidepressant response — dissociation scores (CADSS) do not predict response, but "awe" scores do predict larger MADRS reductions out to 30 days (Price et al.)
- Bioavailability varies critically by route: IV = 100%, intranasal = 30–50%, oral = 10–20% — oral formulations require much higher doses to compensate for gut loss
- Racemic ketamine touches many receptors beyond NMDA; the full antidepressant mechanism is a sum of multiple receptor interactions, not NMDA antagonism alone
Evidence, Efficacy & Durability
- ELECT trial (n=365): IV ketamine non-inferior to ultra-brief RUL ECT in outpatient MDD — notable limitations include comparison to unilateral (not bilateral) ECT and high ECT withdrawal rate post-randomization suggesting expectancy effects; ketamine vs ECT pulled analyses favor ECT, but ELECT N exceeds all prior comparison studies combined
- Esketamine vs quetiapine augmentation (n=676): esketamine significantly outperformed, with ~27% remission — consistent with the broader ~30% remission benchmark
- Durability is a central clinical challenge: single infusion effect ~1 week, multi-infusion series ~1 month; active maintenance strategies (pharmacological, psychosocial, psychotherapeutic, combined TMS+ketamine) are routinely needed
- Active placebo design matters: ketamine vs midazolam shows smaller between-group differences than ketamine vs saline — expectancy inflation from perceived drug effects is a major confounder in psychoactive drug trials
- Fewer prior antidepressant failures predict greater ketamine response (consistent with STAR*D data on diminishing returns with each subsequent failure)
Safety, Regulation & Equity
- Esketamine REMS (Spravato): mandatory in-clinic administration, patient/provider/pharmacy registration, monitoring form per session, adverse event reporting — REMS data from 58,000+ patients over 5 years shows sedation and dissociation in most patients, clinically significant BP elevation (>180 systolic) in ~12% of patients over a treatment lifetime, and serious adverse events (true clinical definition: death/hospitalization/life-threatening) in ~1 in 1,000 sessions; 109 deaths and 70 completed suicides identified via global medical safety surveillance — within expected range for TRD population
- IV racemic ketamine has no regulatory mandate, no registry, no required monitoring — risk of cognitive toxicity with increasing dose/duration is real (largely nonhuman data), and routine cognitive monitoring is recommended but not required
- At-home ketamine models, compounded ketamine nasal sprays, and direct-to-consumer clinics are a growing concern — FDA has explicitly warned compounded ketamine products are not FDA-approved and lack safety data; misuse seizures of ketamine are rising while esketamine misuse is flat (REMS effect)
- Racial and ethnic disparities: clinical trials of racemic ketamine are overwhelmingly white; large claims data show white patients are offered ketamine at higher rates than Black, Hispanic, and Asian patients seen for depression — a structural equity gap
Clinical Pearls — Ketamine Overview
Review Questions — Ketamine Overview
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Ketamine Overview
Stepwise clinical vignettes. Explore all options freely before continuing.
The IPS Intake: 12-Domain Assessment
- Reassess symptoms & diagnosis — don't accept the referring label; probe for bipolarity, psychosis, ADHD, trauma, personality disorders
- "I've tried everything" requires dose, duration, and symptom-specific failure data (response vs remission vs recovery)
- Distinguish tachyphylaxis vs true resistance; state vs trait effects; include paraclinical data (labs, EEG, neuropsych, genetic testing)
- Define success with the patient: symptom reduction vs functional restoration vs patient-defined goals — including what symptom to target first
Circuit-Based Symptom Targeting
- Anhedonia = mesolimbic (VTA→NAc); apathy = frontostriatal; executive dysfunction = DLPFC/frontoparietal; anxiety-driven avoidance = amygdala/salience network
- Passive SI maps to vmPFC/sgACC; OCD to cortico-striatal loops; emotional heaviness to DMN hyperactivity
- ECT acts broadly across networks; TMS targets specific circuits; ketamine restores global synaptic connectivity; VNS/DBS are sustained carriers
- Unexpected early side effects are diagnostic — re-examine formulation before abandoning a modality
5-Axis Modality Selection Framework
- Acuity — emergent (catatonia, psychosis, severe SI) → ECT; subacute stable TRD → TMS/ketamine; chronic refractory → VNS/DBS
- Evidence — most data is sham-controlled, not head-to-head; comparative estimates are directional, not definitive
- Risk-benefit — cognitive risk: ECT > ketamine > TMS; procedural: ECT/VNS/DBS > ketamine > TMS
- Patient factors — psychotic features favor ECT; cognitive concerns favor TMS; bipolar depression well-established for ECT
- Pragmatics/AAA — Available · Accessible · Affordable; non-clinical factors determine real-world feasibility and efficacy
Clinical Pearls — Clinical Decision Making
Review Questions — Clinical Decision Making
Select an answer to reveal the explanation. Explore all choices freely.
Case Simulation — Clinical Decision Making
Stepwise clinical vignettes. Explore all options freely before continuing.
Home Use & Emerging Noninvasive Neuromodulation
A rapidly expanding landscape of prescription and consumer devices — spanning cranioelectrotherapy stimulation (CES), transcranial electrical stimulation (tES), external cranial nerve stimulators, and FDA-cleared digital therapeutics — that patients increasingly access outside the clinic, with or without clinician guidance.
Device Categories & Mechanisms
- CES: surface electrodes (ear clips or scalp sponges), sub-milliamp currents at 0.5–100 Hz; most grandfathered pre-1976; vestibular nerve stimulation at the mastoid process (Modius) is one CES variant with sham-controlled trial data for stress and mood
- tES (tDCS/tACS): sub-threshold electrical stimulation modulating neuronal firing propensity; anodal stimulation depolarizes membrane potential increasing cortical excitability; cathodal stimulation hyperpolarizes and inhibits; montage determines target — standard antidepressant protocol uses anode F3 (left DLPFC) / cathode F4 (right DLPFC); Flow Neuroscience tDCS received US FDA approval December 2025 for moderate-to-severe MDD (both monotherapy and adjunctive)
- External peripheral nerve stimulation: trigeminal (V1 branch, forehead) and occipital stimulators access brainstem monoamine nuclei via the trigeminal cervical complex (parallel to VNS mechanism); auricular/cervical eVNS accesses CN X → NTS → locus coeruleus, dorsal raphe, limbic/prefrontal circuits; vagus nerve also modulates the inflammatory cytokine axis and gut-brain axis
- Digital therapeutics: FDA-cleared software as medical device; CBT-based (insomnia, depression, PTSD, panic, ADHD, substance use, postpartum depression); prescription-required; chronically underutilized in psychiatric practice
Evidence Landscape & Key Trials
- Proliv (eCOT-NS for MDD): FDA-approved via Breakthrough Device pathway; pivotal RCT n=124; HDRS-17 active-sham delta 8.6 points (p=0.029); Cohen's d >0.7; 32% remission vs. sham; adherence 96%; benefit continued accumulating through week 16 open-label extension
- Fisher Wallace Oak (tACS, MDD): triple-blind RCT; 65% vs. 53% response at week 4 per-protocol (p=0.005); primary ITT endpoint (week 2 BDI) narrowly missed significance (p=0.056)
- Flow tDCS Empower trial (FDA approval basis): multicenter, fully remote, placebo-controlled RCT; 10 weeks blinded + 10 weeks open-label; moderate-to-severe MDD (mean HAMD 19.3); non-TRD; MADRS 58% vs. 30% remission; HAMD 45% vs. 25%; NNT ~4; effect size ~0.4; monotherapy response 52.3%; adjunctive response higher in absolute terms but lower odds ratio; real-world sleep benefit: 63% of users with high insomnia normalize sleep scores at 10 weeks
- Monarch TNS (pediatric ADHD): 8-week overnight RCT; Cohen's d=0.5; NNT=3; QEEG frontal biomarker changes correlated with clinical response; auricular eVNS: 5 RCTs show some efficacy for depression but methods too heterogeneous to meta-analyze
Regulatory Landscape, Safety & Clinical Positioning
- FDA regulatory pathway is device-category and indication-specific: a 510k clearance for migraine does not permit a 510k for depression (different product codes); depression and psychiatric indications require more rigorous evidence than neurology indications even for the same device platform
- CES/tES risks are low — primarily skin/scalp irritation under electrodes; burn risk if electrode impedance is high (poor contact, hair interference); syncope risk with high-amplitude eVNS; possible hypomania/mood destabilization in bipolar or psychosis-prone patients — especially with excessive or unsupervised use
- Consumer self-directed use is already happening: patients build DIY tDCS rigs, purchase auricular eVNS devices directly, and access CES devices via downloaded prescription forms; psychiatrists should proactively ask, document, and counsel rather than discover use incidentally
- Two FDA approvals for in-home neuromodulation in depression now exist: Proliv Rx (eCOT-NS, peripheral nerve stimulation, adjunctive, ≥1 prior antidepressant failure) and Flow Neuroscience tDCS (direct cortical stimulation, both monotherapy and adjunctive, non-TRD moderate-to-severe MDD); Flow US launch expected Q2 2025 at ~$500–800 per device, not yet covered by insurance
Clinical Pearls — Emerging Neuromodulation
Review Questions — Emerging Neuromodulation
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Emerging Neuromodulation
Stepwise clinical vignettes. Explore all options freely before continuing.
Scientific Foundations of Interventional Psychiatry
The conceptual, neurophysiological, and historical underpinnings of interventional psychiatry — from circuitopathy models of mental illness through the applied biophysics of brain stimulation modalities and the emerging concept of the field itself.
Circuit-Based Formulation & the Circuitopathy Framework
- Psychiatric and neurological disorders are circuit-level diseases — a DLPFC–sgACC circuit common to depression identified across lesion, TMS, and DBS datasets (Siddiqi et al., 2021); treatment efficacy correlates with degree of circuit modulation
- DSM diagnoses are clinical syndromes — phenomenological clusters of signs and symptoms that gather multiple underlying diseases — not diseases; nine criteria yield 227 combinations meeting criteria for depression, so “what are the biological mechanisms of depression?” is the wrong question, just as it is for left heart failure
- Circuit-based formulation builds on the standard workup rather than replacing it: history, examination, and syndromal formulation first, then identify the symptom dimensions driving this patient’s impairment, map each to its circuit hubs, and select a circuit-level treatment plan — possible even without validated biomarkers
- The circuit level is the right anchor pathophysiologically (behavior, cognition, and emotion are computed in circuits; molecular and synaptic changes matter by modulating circuit dynamics) and therapeutically (drugs act at the molecular level, behavioral therapies at the functional level, devices at the circuit level); causality runs both bottom-up and top-down
- Brain stimulation is personalized (dosed to individual physiology — motor threshold, anatomical targeting, network mapping), targeted (medications produce off-target effects at 20–30%, while stimulation engages the dysregulated circuit and even ECT and VNS are becoming more focal through MST and fascicle-selective taVNS), and scalable (accelerated protocols compress courses to days; in-home wearables are emerging)
Neurology–Psychiatry Split: History, Barriers & the Case for Reunification
- The divide originated in methodology (neurologists had mechanistic brain access; psychiatry evolved introspective and psychodynamic models under Descartes and Freud) — not in biological difference between the conditions they treat; the brain does not respect specialty boundaries
- Patients pay the price: neurological patients frequently have psychiatric comorbidities that go unrecognized (depression in 10–20% of neurology patients; ~5% likely have TRD); psychiatric patients with neurological illness are bounced between specialties for years
- Modalities are heavily siloed: TMS has essentially no clinical neurological approvals despite evidence across stroke rehabilitation, epilepsy, and Parkinson’s; DBS for psychiatric indications exists at only a handful of centers; insurance structures reinforce the divide
- Strategies for reunification: combined neurology–psychiatry training programs, required IPS rotations for residents, multidisciplinary brain health centers, mobile TMS units for rural access, and collaborative care models embedding IPS in neurology and oncology clinics
- Once conditions are anchored at the circuit level, specialty boundaries lose meaning — the same devices already treat neurological and psychiatric indications (DBS for movement disorders and OCD; VNS for epilepsy, stroke rehabilitation, and depression; TMS for migraine, depression, and OCD) — and the shared biological, clinical, and technological framework across invasive, convulsive, noninvasive, and procedural-pharmacological treatments is part of what justifies interventional psychiatry as a subspecialty
Treatment Resistance, Access Crisis, Workforce & Precision Treatment Development
- STAR*D sustained benefit: only 25.7% of MDD patients achieve sustained benefit at 12 months from step 1; drops to 13.7% at step 2, 4.9% at step 3, 3.8% at step 4 — the quantitative case for earlier IPS referral
- Approximately 1 in 3 MDD patients meets TRD criteria; the US suicide rate is at its highest since the Great Depression; yet wait times for psychiatric specialty care run months, and access disparities by geography and payer status are severe
- The “silver tsunami” will worsen both crises: aging-related dementias, Parkinson’s, stroke, and epilepsy will surge; these conditions carry high psychiatric comorbidity rates the specialist workforce cannot absorb under the current siloed model
- The main barrier to IPS adoption is lack of training — not stigma (ranked 6th in US surveys); 1 in 400 eligible US patients is ever offered ECT; device manufacturer training is not a substitute for supervised clinical education
- Treatment development has leaned on serendipity rather than experimental medicine — a mechanistic, biomarker-driven approach that explains pathophysiology in anatomy, physiology, and behavior, identifies a response biomarker tracking clinical change, and finds the protocol that engages it — and treatment selection remains trial and error from group-level evidence; ketamine, neurosteroids, and several TMS protocols are the exceptions
Clinical Pearls — Scientific Foundations
Review Questions — Scientific Foundations
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Scientific Foundations
Stepwise clinical vignettes. Explore all options freely before continuing.
Physical Principles of Stimulation
A device-agnostic physical framework for brain stimulation — transducer, waveform, dose, and titration — explaining why every modality is individually dosed and why the same dose produces different outcomes in different patients.
One Architecture for All Modalities: Generator, Cable, Transducer
- All neuromodulation applies energy through the same chain: a generator that plays a waveform, a cable that carries it, and a transducer where energy passes between device and patient
- The transducer sets the form of energy — electrode (electrical current), coil (magnetic field), vibrating element (ultrasound), light source (light) — and its position, not the generator’s or cable’s, sets where energy enters
- Electrical stimulation always requires two transducers, with current delivered and returned; in DBS, energizing different contacts shifts the stimulated region
- TMS deposits a time-varying magnetic field that induces an electrical current in tissue, and neurons are understood to respond to that induced current
- The generator may be a wheeled console or an implanted can; its size and location do not determine where stimulation occurs
Waveform, Dose, and the Parameter Space
- The waveform is a pulse (intensity, duration) repeated at a frequency to form a pulse train; real waveforms add pulse reversal, bursting, on-time, and noise
- Dose is the waveform plus the type and placement of the transducer, defined by what is delivered rather than by outcome; two devices delivering the same dose have identical effects in the body, so convenience features must be judged separately
- Position controls where, waveform controls how, and intensity does both — higher intensity increases the effect but also enlarges the stimulated region
- Dose must be fully reported for a trial or protocol to be reproducible
- The parameter space has as many dimensions as there are controllable knobs; responses are non-monotonic, parameters interact, and collapsing them into a single metric such as charge has not worked
Why Dose Is Always Titrated: Anatomy, Physiology, and Endpoints
- The same dose delivers different energy to different brains because of anatomy (skull thickness, scalp-to-brain distance; differences as large as tenfold), including with invasive devices, leaving some patients underdosed and others overdosed
- Brain state shapes what stimulation does — stimulation modulates ongoing activity rather than creating new activity — so tasks, symptom provocation, and state-gated or closed-loop delivery function as dose instructions
- The titration protocol is part of the intervention and must be documented, including imaging-based placement decisions; much of the innovation lives in dose instructions, often originating with clinicians
- Symptoms change too slowly to titrate against, so titration uses biomarkers — but a titration biomarker is not necessarily a marker of the disease or the mechanism (the finger twitch; paresthesia in spinal cord stimulation)
- Motor threshold blends anatomy and physiology and assumes transfer across sites and waveforms; anatomy-only model scaling has not replaced it
Clinical Pearls — Physical Principles of Stimulation
Review Questions — Physical Principles of Stimulation
Tap any answer to see its explanation. All choices are freely explorable.
Case Simulation — Physical Principles of Stimulation
Stepwise clinical vignettes. Explore all options freely before continuing.
Ethics & Justice in Interventional Psychiatry
Ethical frameworks, access inequities, consent challenges, workforce composition, and the tensions that distinguish interventional psychiatry from ordinary prescribing — examined across ECT, TMS, ketamine, VNS, DBS, and psychedelics.
What Makes IPS Ethically Distinct
- Procedural consent and monitoring demands exceed ordinary prescribing
- Often deployed in refractory, disabling, or life-threatening illness — raising hope stakes
- Resource intensity and scarcity amplify every ethical decision
- Transference and countertransference dynamics are heightened in procedure-based care
- Historical missteps (lobotomy, unmodified ECT) demand ongoing humility
Access, Equity & Workforce
- Access is an ethical outcome — an unreachable treatment is not a success
- ECT: 49% of providers at academic centers; only 1% of providers are Black or African American
- Ketamine: >40% of clinics offer at-home treatment; <30% run by psychiatrists
- DBS/VNS face opposite problem: evidence without meaningful geographic reach
- Workforce composition must reflect patient population — data gaps for TMS and ketamine persist
Consent, Monitoring & Commercialization
- Patient desperation can compromise genuine voluntariness — consent must account for this
- ECT over-objection and psychedelic consent thresholds remain live ethical debates
- Modality-limited clinics risk structural bias: what is best becomes what is available
- Commercial motives can distort treatment selection toward profitable over optimal
- Ethical excellence means pluralistic evaluation, medical responsibility, and justice orientation
Clinical Pearls — Ethics & Justice
Review Questions — Ethics & Justice
Select an answer to reveal the explanation. Explore all choices freely.
Case Simulation — Ethics & Justice
Stepwise clinical vignettes. Explore all options freely before continuing.